The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?
DOI:
https://doi.org/10.21467/preprints.373Abstract
The authors of this brief commentary give an update on the results of the last studies on the antibody response to the so-called “booster” administration of the Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV)-2 vaccines, with particular reference to the new “omicron” variant. A brief overview of the immunological response to this infection is also provided, with the advise that a serological test before the third dose of the vaccine is not recommended, as stated by the Food and Drug Administration (FDA).
Keywords:
SARS-CoV-2, CoVID-19, VaccineDownloads
References
Kemp F, Proverbio D, Aalto A, Mombaerts L, Fouquier d'Hérouël A, Husch A, Ley C, Gonçalves J, Skupin A, Magni S. Modelling COVID-19 dynamics and potential for herd immunity by vaccination in Austria, Luxembourg and Sweden. J Theor Biol. 2021 Dec 7;530:110874. doi: 10.1016/j.jtbi.2021.110874. Epub 2021 Aug 21. PMID: 34425136; PMCID: PMC8378986.
Paul KT, Zimmermann BM, Corsico P, Fiske A, Geiger S, Johnson S, Kuiper JML, Lievevrouw E, Marelli L, Prainsack B, Spahl W, Van Hoyweghen I. Anticipating hopes, fears and expectations towards COVID-19 vaccines: A qualitative interview study in seven European countries. SSM Qual Res Health. 2022 Dec;2:100035. doi: 10.1016/j.ssmqr.2021.100035. Epub 2022 Jan 4. PMID: 35013736; PMCID: PMC8731673.
Kertes J, Gez SB, Saciuk Y, Supino-Rosin L, Stein NS, Mizrahi-Reuveni M, Zohar AE. Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel. Emerg Infect Dis. 2022 Feb;28(2):338-346. doi: 10.3201/eid2802.211834. Epub 2021 Dec 14. PMID: 34906291.
Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, Wan Y, Huang Y, Song J, Fu Z, Wang H, Guo J, Jiang N, Fan M, Zhou Y, Zhao Y, Zhang Q, Liu Q, Lv J, Li P, Qiu C, Zhang W. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440. PMID: 34935594; PMCID: PMC8788341.
Lythgoe MP, Middleton P. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. JAMA Netw Open. 2021 Jun 1;4(6):e2114531. doi: 10.1001/jamanetworkopen.2021.14531. PMID: 34170306; PMCID: PMC8233699.
Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, Winders B, Lee JY, Lee DX, Messer WB, Curlin ME, Tafesse FG. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022 Jan 25:eabn8014. doi: 10.1126/sciimmunol.abn8014. Epub ahead of print. PMID: 35076258.
Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27516. Epub ahead of print. PMID: 34897752.
Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, Adams L, Kjaer S, Kelly G, Warchal S, Sawyer C, Kavanagh C, Queval CJ, Ngai Y, Hatipoglu E, Ambrose K, Hindmarsh S, Beale R, Gamblin S, Howell M, Kassiotis G, Libri V, Williams B, Gandhi S, Swanton C, Bauer DL. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet. 2022 Jan 19:S0140-6736(22)00092-7. doi: 10.1016/S0140-6736(22)00092-7. Epub ahead of print. PMID: 35065005.
Ireland G, Whitaker H, Ladhani SN, Baawuah F, Subbarao S, Linley E, Warrener L, O'Brien M, Whillock C, Martin O, Moss P, Ramsay ME, Amirthalingam G, Brown KE. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101114. PMID: 34991777.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PMID: 34473343; PMCID: PMC8411904.
Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, Izcovich A, Mangala S, Ge L, Han MA, Agoritsas T, Arnold D, Ávila C, Chu DK, Couban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochwerg B, Switzer C, Vandvik PO, Vernooij RW, Wang Y, Yao L, Guyatt GH, Brignardello-Petersen R. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231. doi: 10.1136/bmj.n2231. PMID: 34556486; PMCID: PMC8459162.
Downloads
Posted
Section
Categories
License
Copyright (c) 2022 Franco Borruto, Ciro Comparetto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.
